{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:48:06Z","timestamp":1791337686597,"version":"4.3.1"},"reference-count":156,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T00:00:00Z","timestamp":1640908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T00:00:00Z","timestamp":1640908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001602","name":"Science Foundation Ireland","doi-asserted-by":"crossref","award":["16-FRL-3845"],"award-info":[{"award-number":["16-FRL-3845"]}],"id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["ICMx"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Severe viral pneumonia is a significant cause of morbidity and mortality globally, whether due to outbreaks of endemic viruses, periodic viral epidemics, or the rarer but devastating global viral pandemics. While limited anti-viral therapies exist, there is a paucity of direct therapies to directly attenuate viral pneumonia-induced lung injury, and management therefore remains largely supportive. Mesenchymal stromal\/stem cells (MSCs) are receiving considerable attention as a cytotherapeutic for viral pneumonia. Several properties of MSCs position them as a promising therapeutic strategy for viral pneumonia-induced lung injury as demonstrated in pre-clinical studies in relevant models. More recently, early phase clinical studies have demonstrated a reassuring safety profile of these cells. These investigations have taken on an added importance and urgency during the COVID-19 pandemic, with multiple trials in progress across the globe. In parallel with clinical translation, strategies are being investigated to enhance the therapeutic potential of these cells in vivo, with different MSC tissue sources, specific cellular products including cell-free options, and strategies to \u2018licence\u2019 or \u2018pre-activate\u2019 these cells, all being explored. This review will assess the therapeutic potential of MSC-based therapies for severe viral pneumonia. It will describe the aetiology and epidemiology of severe viral pneumonia, describe current therapeutic approaches, and examine the data suggesting therapeutic potential of MSCs for severe viral pneumonia in pre-clinical and clinical studies. The challenges and opportunities for MSC-based therapies will then be considered.<\/jats:p>","DOI":"10.1186\/s40635-021-00424-5","type":"journal-article","created":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T00:02:47Z","timestamp":1640908967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Mesenchymal stem\/stromal cell-based therapies for severe viral pneumonia: therapeutic potential and challenges"],"prefix":"10.1186","volume":"9","author":[{"given":"C. H.","family":"Masterson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ceccato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Artigas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. R.","family":"Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Rolandsson Enes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. J.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"McAuley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Matthay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"English","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. F.","family":"Curley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1246-9573","authenticated-orcid":false,"given":"J. G.","family":"Laffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,31]]},"reference":[{"key":"424_CR1","doi-asserted-by":"publisher","first-page":"600711","DOI":"10.3389\/fcell.2021.600711","volume":"9","author":"SC Abreu","year":"2021","unstructured":"Abreu SC, Lopes-Pacheco M, Weiss DJ, Rocco PRM (2021) Mesenchymal Stromal Cell-Derived Extracellular Vesicles in Lung Diseases: Current Status and Perspectives. Front Cell Dev Biol 9:600711","journal-title":"Front Cell Dev Biol"},{"key":"424_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1183\/13993003.00858-2020","volume":"55","author":"M Khoury","year":"2020","unstructured":"Khoury M, Cuenca J, Cruz FF, Figueroa FE, Rocco PRM, Weiss DJ (2020) Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19. Eur Respir J 55:8","journal-title":"Eur Respir J"},{"key":"424_CR3","first-page":"2382","volume":"373","author":"Jain S, Self WH, Wunderink RG, Team CES","year":"2015","unstructured":"Jain S, Self WH, Wunderink RG, Team CES (2015) Community-Acquired Pneumonia Requiring Hospitalization. N Engl J Med 373:2382","journal-title":"N Engl J Med"},{"key":"424_CR4","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1164\/rccm.201112-2240OC","volume":"186","author":"SH Choi","year":"2012","unstructured":"Choi SH, Hong SB, Ko GB, Lee Y, Park HJ, Park SY, Moon SM, Cho OH, Park KH, Chong YP, Kim SH, Huh JW, Sung H, Do KH, Lee SO, Kim MN, Jeong JY, Lim CM, Kim YS, Woo JH, Koh Y (2012) Viral infection in patients with severe pneumonia requiring intensive care unit admission. Am J Respir Crit Care Med 186:325\u2013332","journal-title":"Am J Respir Crit Care Med"},{"key":"424_CR5","volume-title":"Burden of Influenza","author":"Centers for Disease Control and Prevention NCfIaRDN","year":"2021","unstructured":"Centers for Disease Control and Prevention NCfIaRDN (2021) Burden of Influenza. Book Burden of Influenza, New York"},{"key":"424_CR6","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","volume":"391","author":"AD Iuliano","year":"2018","unstructured":"Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, Cohen C, Gran JM, Schanzer D, Cowling BJ, Wu P, Kyncl J, Ang LW, Park M, Redlberger-Fritz M, Yu H, Espenhain L, Krishnan A, Emukule G, van Asten L, Pereira da Silva S, Aungkulanon S, Buchholz U, Widdowson MA, Bresee JS, Collaborator G-A, N, (2018) Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet 391:1285\u20131300","journal-title":"Lancet"},{"key":"424_CR7","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1086\/501539","volume":"27","author":"HM Babcock","year":"2006","unstructured":"Babcock HM, Merz LR, Fraser VJ (2006) Is influenza an influenza-like illness? Clinical presentation of influenza in hospitalized patients. Infect Control Hosp Epidemiol 27:266\u2013270","journal-title":"Infect Control Hosp Epidemiol"},{"key":"424_CR8","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s13054-019-2491-9","volume":"23","author":"EJ Chow","year":"2019","unstructured":"Chow EJ, Doyle JD, Uyeki TM (2019) Influenza virus-related critical illness: prevention, diagnosis, treatment. Crit Care 23:214","journal-title":"Crit Care"},{"key":"424_CR9","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.ccc.2013.06.003","volume":"29","author":"CD Ramsey","year":"2013","unstructured":"Ramsey CD, Kumar A (2013) Influenza and endemic viral pneumonia. Crit Care Clin 29:1069\u20131086","journal-title":"Crit Care Clin"},{"key":"424_CR10","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1136\/jim-2018-000712","volume":"66","author":"D Dandachi","year":"2018","unstructured":"Dandachi D, Rodriguez-Barradas MC (2018) Viral pneumonia: etiologies and treatment. J Investig Med 66:957\u2013965","journal-title":"J Investig Med"},{"key":"424_CR11","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1016\/S0140-6736(06)69895-4","volume":"368","author":"CJ Murray","year":"2006","unstructured":"Murray CJ, Lopez AD, Chin B, Feehan D, Hill KH (2006) Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918\u201320 pandemic: a quantitative analysis. Lancet 368:2211\u20132218","journal-title":"Lancet"},{"key":"424_CR12","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1056\/NEJMoa0904252","volume":"361","author":"R Perez-Padilla","year":"2009","unstructured":"Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, Hernandez M, Quinones-Falconi F, Bautista E, Ramirez-Venegas A, Rojas-Serrano J, Ormsby CE, Corrales A, Higuera A, Mondragon E, Cordova-Villalobos JA, Influenza IWGo, (2009) Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med 361:680\u2013689","journal-title":"N Engl J Med"},{"key":"424_CR13","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMra1000449","volume":"362","author":"E Bautista","year":"2010","unstructured":"Writing Committee of the WHOCoCAoPI, Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, Uyeki TM, Zaki SR, Hayden FG, Hui DS, Kettner JD, Kumar A, Lim M, Shindo N, Penn C, Nicholson KG (2010) Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 362:1708\u20131719","journal-title":"N Engl J Med"},{"key":"424_CR14","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/MCP.0000000000000047","volume":"20","author":"KK To","year":"2014","unstructured":"To KK, Chan JF, Yuen KY (2014) Viral lung infections: epidemiology, virology, clinical features, and management of avian influenza A(H7N9). Curr Opin Pulm Med 20:225\u2013232","journal-title":"Curr Opin Pulm Med"},{"key":"424_CR15","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMra032498","volume":"349","author":"JS Peiris","year":"2003","unstructured":"Peiris JS, Yuen KY, Osterhaus AD, Stohr K (2003) The severe acute respiratory syndrome. N Engl J Med 349:2431\u20132441","journal-title":"N Engl J Med"},{"key":"424_CR16","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.ccc.2013.07.003","volume":"29","author":"N Lee","year":"2013","unstructured":"Lee N, Qureshi ST (2013) Other viral pneumonias: coronavirus, respiratory syncytial virus, adenovirus, hantavirus. Crit Care Clin 29:1045\u20131068","journal-title":"Crit Care Clin"},{"key":"424_CR17","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","volume":"367","author":"AM Zaki","year":"2012","unstructured":"Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367:1814\u20131820","journal-title":"N Engl J Med"},{"key":"424_CR18","unstructured":"WHO (2021) Middle East respiratory syndrome coronavirus (MERS-CoV). In: Book Middle East respiratory syndrome coronavirus (MERS-CoV)"},{"key":"424_CR19","unstructured":"Medicine JHU (2021) Coronavirus Resource Center - Global Map. In: Book Coronavirus Resource Center - Global Map"},{"key":"424_CR20","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s00134-020-06294-x","volume":"47","author":"Network C-IGobotR, the C-ICUI","year":"2021","unstructured":"Network C-IGobotR, the C-ICUI (2021) Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. Intensive Care Med 47:60\u201373","journal-title":"Intensive Care Med"},{"key":"424_CR21","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1001\/jamainternmed.2020.3539","volume":"180","author":"G Grasselli","year":"2020","unstructured":"Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, Bonanomi E, Cabrini L, Carlesso E, Castelli G, Cattaneo S, Cereda D, Colombo S, Coluccello A, Crescini G, Forastieri Molinari A, Foti G, Fumagalli R, Iotti GA, Langer T, Latronico N, Lorini FL, Mojoli F, Natalini G, Pessina CM, Ranieri VM, Rech R, Scudeller L, Rosano A, Storti E, Thompson BT, Tirani M, Villani PG, Pesenti A, Cecconi M, Network C-LI (2020) Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy. JAMA Intern Med 180:1345\u20131355","journal-title":"JAMA Intern Med"},{"key":"424_CR22","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","volume":"180","author":"C Wu","year":"2020","unstructured":"Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y (2020) Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 180:934\u2013943","journal-title":"JAMA Intern Med"},{"key":"424_CR23","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1164\/rccm.202006-2405OC","volume":"203","author":"ZJ Lim","year":"2021","unstructured":"Lim ZJ, Subramaniam A, Ponnapa Reddy M, Blecher G, Kadam U, Afroz A, Billah B, Ashwin S, Kubicki M, Bilotta F, Curtis JR, Rubulotta F (2021) Case fatality rates for patients with COVID-19 requiring invasive mechanical ventilation. a meta-analysis. Am J Respir Crit Care Med 203:54\u201366","journal-title":"Am J Respir Crit Care Med"},{"key":"424_CR24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13054-021-03551-3","volume":"25","author":"C Jung","year":"2021","unstructured":"Jung C, Flaatten H, Fjolner J, Bruno RR, Wernly B, Artigas A, Bollen Pinto B, Schefold JC, Wolff G, Kelm M, Beil M, Sviri S, van Heerden PV, Szczeklik W, Czuczwar M, Elhadi M, Joannidis M, Oeyen S, Zafeiridis T, Marsh B, Andersen FH, Moreno R, Cecconi M, Leaver S, Boumendil A, De Lange DW, Guidet B (2021) The impact of frailty on survival in elderly intensive care patients with COVID-19: the COVIP study. Crit Care 25:149","journal-title":"Crit Care"},{"key":"424_CR25","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.chest.2021.02.062","volume":"160","author":"Gonzalez J, Benitez ID, Carmona P, Santisteve S, Monge A, Moncusi-Moix A, Gort-Paniello C, Pinilla L, Carratala A, Zuil M, Ferrer R, Ceccato A, Fernandez L, Motos A, Riera J, Menendez R, Garcia-Gasulla D, Penuelas O, Bermejo-Martin JF, Labarca G, Caballero J, Torres G, de Gonzalo-Calvo D, Torres A, Barbe F, Project C","year":"2021","unstructured":"Gonzalez J, Benitez ID, Carmona P, Santisteve S, Monge A, Moncusi-Moix A, Gort-Paniello C, Pinilla L, Carratala A, Zuil M, Ferrer R, Ceccato A, Fernandez L, Motos A, Riera J, Menendez R, Garcia-Gasulla D, Penuelas O, Bermejo-Martin JF, Labarca G, Caballero J, Torres G, de Gonzalo-Calvo D, Torres A, Barbe F, Project C (2021) Pulmonary Function and Radiologic Features in Survivors of Critical COVID-19: A 3-Month Prospective Cohort. Chest 160:187\u2013198","journal-title":"Chest"},{"key":"424_CR26","first-page":"9","volume":"23","author":"E Barbeta","year":"2021","unstructured":"Barbeta E, Benegas M, Sanchez M, Motos A, Ferrer M, Ceccato A, Lopez R, Bueno L, Artigas RM, Ferrando C, Fernandez-Barat L, Albacar N, Badia JR, Lopez T, Sandoval E, Toapanta D, Castro P, Soriano A, Torres A, Care CCC, G, (2021) Risk Factors and Clinical Impact of Fibrotic-Like Changes and the Organizing Pneumonia Pattern in Patients with COVID-19- and Non-COVID-19-induced Acute Respiratory Distress Syndrome. Arch Bronconeumol 23:9","journal-title":"Arch Bronconeumol"},{"key":"424_CR27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41572-019-0069-0","volume":"5","author":"MA Matthay","year":"2019","unstructured":"Matthay MA, Zemans RL, Zimmerman GA, Arabi YM, Beitler JR, Mercat A, Herridge M, Randolph AG, Calfee CS (2019) Acute respiratory distress syndrome. Nat Rev Dis Primers 5:18","journal-title":"Nat Rev Dis Primers"},{"key":"424_CR28","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1164\/rccm.202005-1885OC","volume":"202","author":"S Hue","year":"2020","unstructured":"Hue S, Beldi-Ferchiou A, Bendib I, Surenaud M, Fourati S, Frapard T, Rivoal S, Razazi K, Carteaux G, Delfau-Larue MH, Mekontso-Dessap A, Audureau E, de Prost N (2020) Uncontrolled Innate and Impaired Adaptive Immune Responses in Patients with COVID-19 Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med 202:1509\u20131519","journal-title":"Am J Respir Crit Care Med"},{"key":"424_CR29","doi-asserted-by":"publisher","first-page":"4620","DOI":"10.1073\/pnas.0308001101","volume":"101","author":"MN Matrosovich","year":"2004","unstructured":"Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD (2004) Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc Natl Acad Sci U S A 101:4620\u20134624","journal-title":"Proc Natl Acad Sci U S A"},{"key":"424_CR30","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/cr.2013.92","volume":"23","author":"N Wang","year":"2013","unstructured":"Wang N, Shi X, Jiang L, Zhang S, Wang D, Tong P, Guo D, Fu L, Cui Y, Liu X, Arledge KC, Chen YH, Zhang L, Wang X (2013) Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res 23:986\u2013993","journal-title":"Cell Res"},{"key":"424_CR31","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ajpath.2015.09.014","volume":"186","author":"DK Meyerholz","year":"2016","unstructured":"Meyerholz DK, Lambertz AM, McCray PB Jr (2016) Dipeptidyl Peptidase 4 Distribution in the Human Respiratory Tract: Implications for the Middle East Respiratory Syndrome. Am J Pathol 186:78\u201386","journal-title":"Am J Pathol"},{"key":"424_CR32","doi-asserted-by":"crossref","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Muller MA, Drosten C, Pohlmann S, (2020) SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 181: 271\u2013280","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"424_CR33","doi-asserted-by":"publisher","first-page":"30113","DOI":"10.1074\/jbc.M505111200","volume":"280","author":"DW Lambert","year":"2005","unstructured":"Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, Smith AI, Hooper NM, Turner AJ (2005) Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem 280:30113\u201330119","journal-title":"J Biol Chem"},{"key":"424_CR34","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1128\/JVI.02202-13","volume":"88","author":"A Heurich","year":"2014","unstructured":"Heurich A, Hofmann-Winkler H, Gierer S, Liepold T, Jahn O, Pohlmann S (2014) TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. J Virol 88:1293\u20131307","journal-title":"J Virol"},{"key":"424_CR35","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1128\/CMR.00103-20","volume":"34","author":"N Clementi","year":"2021","unstructured":"Clementi N, Ghosh S, De Santis M, Castelli M, Criscuolo E, Zanoni I, Clementi M, Mancini N (2021) Viral Respiratory Pathogens and Lung Injury. Clin Microbiol Rev 34:87","journal-title":"Clin Microbiol Rev"},{"key":"424_CR36","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1164\/rccm.202005-1583OC","volume":"202","author":"OJ McElvaney","year":"2020","unstructured":"McElvaney OJ, McEvoy NL, McElvaney OF, Carroll TP, Murphy MP, Dunlea DM, Ni Choileain O, Clarke J, O\u2019Connor E, Hogan G, Ryan D, Sulaiman I, Gunaratnam C, Branagan P, O\u2019Brien ME, Morgan RK, Costello RW, Hurley K, Walsh S, de Barra E, McNally C, McConkey S, Boland F, Galvin S, Kiernan F, O\u2019Rourke J, Dwyer R, Power M, Geoghegan P, Larkin C, O\u2019Leary RA, Freeman J, Gaffney A, Marsh B, Curley GF, McElvaney NG (2020) Characterization of the Inflammatory Response to Severe COVID-19 Illness. Am J Respir Crit Care Med 202:812\u2013821","journal-title":"Am J Respir Crit Care Med"},{"key":"424_CR37","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1172\/JCI137244","volume":"130","author":"G Chen","year":"2020","unstructured":"Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H, Zhang X, Zhang M, Wu S, Song J, Chen T, Han M, Li S, Luo X, Zhao J, Ning Q (2020) Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 130:2620\u20132629","journal-title":"J Clin Invest"},{"key":"424_CR38","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/infdis\/jiv550","volume":"213","author":"GS Schulert","year":"2016","unstructured":"Schulert GS, Zhang M, Fall N, Husami A, Kissell D, Hanosh A, Zhang K, Davis K, Jentzen JM, Napolitano L, Siddiqui J, Smith LB, Harms PW, Grom AA, Cron RQ (2016) Whole-Exome Sequencing Reveals Mutations in Genes Linked to Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome in Fatal Cases of H1N1 Influenza. J Infect Dis 213:1180\u20131188","journal-title":"J Infect Dis"},{"key":"424_CR39","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, Collaboration HAS, UK, (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395:1033\u20131034","journal-title":"Lancet"},{"key":"424_CR40","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1001\/jamainternmed.2020.3313","volume":"180","author":"P Sinha","year":"2020","unstructured":"Sinha P, Matthay MA, Calfee CS (2020) Is a \u201cCytokine Storm\u201d Relevant to COVID-19? JAMA Intern Med 180:1152\u20131154","journal-title":"JAMA Intern Med"},{"key":"424_CR41","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S2213-2600(21)00103-X","volume":"9","author":"OJ McElvaney","year":"2021","unstructured":"McElvaney OJ, Curley GF, Rose-John S, McElvaney NG (2021) Interleukin-6: obstacles to targeting a complex cytokine in critical illness. Lancet Respir Med 9:643\u2013654","journal-title":"Lancet Respir Med"},{"key":"424_CR42","doi-asserted-by":"publisher","first-page":"e0256226","DOI":"10.1371\/journal.pone.0256226","volume":"16","author":"F Palmas","year":"2021","unstructured":"Palmas F, Clarke J, Colas RA, Gomez EA, Keogh A, Boylan M, McEvoy N, McElvaney OJ, McElvaney O, Alalqam R, McElvaney NG, Curley GF, Dalli J (2021) Dysregulated plasma lipid mediator profiles in critically ill COVID-19 patients. PLoS ONE 16:e0256226","journal-title":"PLoS ONE"},{"key":"424_CR43","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","volume":"181","author":"D Blanco-Melo","year":"2020","unstructured":"Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Moller R, Jordan TX, Oishi K, Panis M, Sachs D, Wang TT, Schwartz RE, Lim JK, Albrecht RA, tenOever BR (2020) Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell 181:1036\u20131045","journal-title":"Cell"},{"key":"424_CR44","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.chom.2020.04.017","volume":"27","author":"Z Zhou","year":"2020","unstructured":"Zhou Z, Ren L, Zhang L, Zhong J, Xiao Y, Jia Z, Guo L, Yang J, Wang C, Jiang S, Yang D, Zhang G, Li H, Chen F, Xu Y, Chen M, Gao Z, Yang J, Dong J, Liu B, Zhang X, Wang W, He K, Jin Q, Li M, Wang J (2020) Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients. Cell Host Microbe 27:883\u2013890","journal-title":"Cell Host Microbe"},{"key":"424_CR45","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jinf.2020.07.016","volume":"81","author":"H Shuai","year":"2020","unstructured":"Shuai H, Chu H, Hou Y, Yang D, Wang Y, Hu B, Huang X, Zhang X, Chai Y, Cai JP, Chan JF, Yuen KY (2020) Differential immune activation profile of SARS-CoV-2 and SARS-CoV infection in human lung and intestinal cells: Implications for treatment with IFN-beta and IFN inducer. J Infect 81:e1\u2013e10","journal-title":"J Infect"},{"key":"424_CR46","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.chom.2016.01.007","volume":"19","author":"R Channappanavar","year":"2016","unstructured":"Channappanavar R, Fehr AR, Vijay R, Mack M, Zhao J, Meyerholz DK, Perlman S (2016) Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell Host Microbe 19:181\u2013193","journal-title":"Cell Host Microbe"},{"key":"424_CR47","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2015432","volume":"383","author":"M Ackermann","year":"2020","unstructured":"Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, Vanstapel A, Werlein C, Stark H, Tzankov A, Li WW, Li VW, Mentzer SJ, Jonigk D (2020) Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med 383:120\u2013128","journal-title":"N Engl J Med"},{"key":"424_CR48","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/path.1570","volume":"203","author":"I Hamming","year":"2004","unstructured":"Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H (2004) Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 203:631\u2013637","journal-title":"J Pathol"},{"key":"424_CR49","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","volume":"395","author":"Z Varga","year":"2020","unstructured":"Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H (2020) Endothelial cell infection and endotheliitis in COVID-19. Lancet 395:1417\u20131418","journal-title":"Lancet"},{"key":"424_CR50","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1111\/jth.15409","volume":"19","author":"SE Ward","year":"2021","unstructured":"Ward SE, Fogarty H, Karampini E, Lavin M, Schneppenheim S, Dittmer R, Morrin H, Glavey S, Ni Cheallaigh C, Bergin C, Martin-Loeches I, Mallon PW, Curley GF, Baker RI, Budde U, O\u2019Sullivan JM, Krish JS (2021) ADAMTS13 regulation of VWF multimer distribution in severe COVID-19. J Thromb Haemost 19:1914\u20131921","journal-title":"J Thromb Haemost"},{"key":"424_CR51","unstructured":"Prevention CCfdca (2021) Influenza (Flu) For Clinicians: Antiviral Medication. In: Book Influenza (Flu) For Clinicians: Antiviral Medication"},{"key":"424_CR52","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/v13040624","volume":"13","author":"Y Bai","year":"2021","unstructured":"Bai Y, Jones JC, Wong SS, Zanin M (2021) Antivirals Targeting the Surface Glycoproteins of Influenza Virus: Mechanisms of Action and Resistance. Viruses 13:3","journal-title":"Viruses"},{"key":"424_CR53","unstructured":"Control EECfDPa (2017) Expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza. In: Book Expert opinion on neuraminidase inhibitors for the preventiona and treatment of influenza. ECDC"},{"key":"424_CR54","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/QCO.0000000000000532","volume":"32","author":"FG Hayden","year":"2019","unstructured":"Hayden FG, Shindo N (2019) Influenza virus polymerase inhibitors in clinical development. Curr Opin Infect Dis 32:176\u2013186","journal-title":"Curr Opin Infect Dis"},{"key":"424_CR55","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.jiac.2017.06.008","volume":"23","author":"H Ikematsu","year":"2017","unstructured":"Ikematsu H, Kawai N, Iwaki N, Kashiwagi S (2017) Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate; comparison of the 2011\/12 to 2015\/16 Japanese influenza seasons. J Infect Chemother 23:627\u2013633","journal-title":"J Infect Chemother"},{"issue":"Suppl 1","key":"424_CR56","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1086\/591851","volume":"48","author":"F Hayden","year":"2009","unstructured":"Hayden F (2009) Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis 48(Suppl 1):S3-13","journal-title":"Clin Infect Dis"},{"key":"424_CR57","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S1473-3099(20)30004-9","volume":"20","author":"MG Ison","year":"2020","unstructured":"Ison MG, Portsmouth S, Yoshida Y, Shishido T, Mitchener M, Tsuchiya K, Uehara T, Hayden FG (2020) Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis 20:1204\u20131214","journal-title":"Lancet Infect Dis"},{"key":"424_CR58","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3390\/molecules26040880","volume":"26","author":"SE Mtambo","year":"2021","unstructured":"Mtambo SE, Amoako DG, Somboro AM, Agoni C, Lawal MM, Gumede NS, Khan RB, Kumalo HM (2021) Influenza Viruses: Harnessing the Crucial Role of the M2 Ion-Channel and Neuraminidase toward Inhibitor Design. Molecules 26:67","journal-title":"Molecules"},{"key":"424_CR59","doi-asserted-by":"publisher","first-page":"5115","DOI":"10.2174\/0929867324666170920165926","volume":"25","author":"J Han","year":"2018","unstructured":"Han J, Perez J, Schafer A, Cheng H, Peet N, Rong L, Manicassamy B (2018) Influenza Virus: Small Molecule Therapeutics and Mechanisms of Antiviral Resistance. Curr Med Chem 25:5115\u20135127","journal-title":"Curr Med Chem"},{"key":"424_CR60","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1164\/rccm.201311-2041LE","volume":"189","author":"S Herold","year":"2014","unstructured":"Herold S, Hoegner K, Vadasz I, Gessler T, Wilhelm J, Mayer K, Morty RE, Walmrath HD, Seeger W, Lohmeyer J (2014) Inhaled granulocyte\/macrophage colony-stimulating factor as treatment of pneumonia-associated acute respiratory distress syndrome. Am J Respir Crit Care Med 189:609\u2013611","journal-title":"Am J Respir Crit Care Med"},{"key":"424_CR61","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/CCM.0b013e31822d7bf0","volume":"40","author":"R Paine 3rd","year":"2012","unstructured":"Paine R 3rd, Standiford TJ, Dechert RE, Moss M, Martin GS, Rosenberg AL, Thannickal VJ, Burnham EL, Brown MB, Hyzy RC (2012) A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury. Crit Care Med 40:90\u201397","journal-title":"Crit Care Med"},{"key":"424_CR62","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12931-017-0708-5","volume":"19","author":"ES Halstead","year":"2018","unstructured":"Halstead ES, Umstead TM, Davies ML, Kawasawa YI, Silveyra P, Howyrlak J, Yang L, Guo W, Hu S, Hewage EK, Chroneos ZC (2018) GM-CSF overexpression after influenza a virus infection prevents mortality and moderates M1-like airway monocyte\/macrophage polarization. Respir Res 19:3","journal-title":"Respir Res"},{"key":"424_CR63","unstructured":"Services. USDoHH (2019) Influenza Therapeutics Program. In: Book Influenza Therapeutics Program"},{"key":"424_CR64","unstructured":"Services. USDoHH (2019) Influenza & emerging infectious diseases. In: Book influenza & emerging infectious diseases"},{"key":"424_CR65","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.antiviral.2019.04.006","volume":"167","author":"JH Beigel","year":"2019","unstructured":"Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, Sims AC (2019) Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference. Antiviral Res 167:45\u201367","journal-title":"Antiviral Res"},{"key":"424_CR66","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/v13050780","volume":"13","author":"S Weis","year":"2021","unstructured":"Weis S, TeVelthuis AJW (2021) Influenza Virus RNA Synthesis and the Innate Immune Response. Viruses 13:8","journal-title":"Viruses"},{"key":"424_CR67","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/imr.12851","volume":"295","author":"A Bahadoran","year":"2020","unstructured":"Bahadoran A, Bezavada L, Smallwood HS (2020) Fueling influenza and the immune response: Implications for metabolic reprogramming during influenza infection and immunometabolism. Immunol Rev 295:140\u2013166","journal-title":"Immunol Rev"},{"key":"424_CR68","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41435-021-00140-w","volume":"22","author":"WG Land","year":"2021","unstructured":"Land WG (2021) Role of DAMPs in respiratory virus-induced acute respiratory distress syndrome-with a preliminary reference to SARS-CoV-2 pneumonia. Genes Immun 22:141\u2013160","journal-title":"Genes Immun"},{"key":"424_CR69","doi-asserted-by":"publisher","first-page":"e0147170","DOI":"10.1371\/journal.pone.0147170","volume":"11","author":"LA McIntyre","year":"2016","unstructured":"McIntyre LA, Moher D, Fergusson DA, Sullivan KJ, Mei SH, Lalu M, Marshall J, McLeod M, Griffin G, Grimshaw J, Turgeon A, Avey MT, Rudnicki MA, Jazi M, Fishman J, Stewart DJ, Biology CCCT, G, (2016) Efficacy of Mesenchymal Stromal Cell Therapy for Acute Lung Injury in Preclinical Animal Models: A Systematic Review. PLoS ONE 11:e0147170","journal-title":"PLoS ONE"},{"key":"424_CR70","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40635-019-0235-4","volume":"7","author":"CH Masterson","year":"2019","unstructured":"Masterson CH, Curley GF, Laffey JG (2019) Modulating the distribution and fate of exogenously delivered MSCs to enhance therapeutic potential: knowns and unknowns. Intensive Care Med Exp 7:41","journal-title":"Intensive Care Med Exp"},{"key":"424_CR71","doi-asserted-by":"publisher","first-page":"5265","DOI":"10.1038\/s41598-021-83894-7","volume":"11","author":"CH Masterson","year":"2021","unstructured":"Masterson CH, Tabuchi A, Hogan G, Fitzpatrick G, Kerrigan SW, Jerkic M, Kuebler WM, Laffey JG, Curley GF (2021) Intra-vital imaging of mesenchymal stromal cell kinetics in the pulmonary vasculature during infection. Sci Rep 11:5265","journal-title":"Sci Rep"},{"key":"424_CR72","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1183\/13993003.02369-2017","volume":"51","author":"J Armitage","year":"2018","unstructured":"Armitage J, Tan DBA, Troedson R, Young P, Lam KV, Shaw K, Sturm M, Weiss DJ, Moodley YP (2018) Mesenchymal stromal cell infusion modulates systemic immunological responses in stable COPD patients: a phase I pilot study. Eur Respir J 51:8","journal-title":"Eur Respir J"},{"key":"424_CR73","doi-asserted-by":"publisher","first-page":"e10088","DOI":"10.1371\/journal.pone.0010088","volume":"5","author":"RS Waterman","year":"2010","unstructured":"Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM (2010) A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS ONE 5:e10088","journal-title":"PLoS ONE"},{"key":"424_CR74","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1089\/scd.2016.0349","volume":"26","author":"GD Kusuma","year":"2017","unstructured":"Kusuma GD, Carthew J, Lim R, Frith JE (2017) Effect of the Microenvironment on Mesenchymal Stem Cell Paracrine Signaling: Opportunities to Engineer the Therapeutic Effect. Stem Cells Dev 26:617\u2013631","journal-title":"Stem Cells Dev"},{"key":"424_CR75","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1164\/rccm.201802-0356OC","volume":"199","author":"D Islam","year":"2019","unstructured":"Islam D, Huang Y, Fanelli V, Delsedime L, Wu S, Khang J, Han B, Grassi A, Li M, Xu Y, Luo A, Wu J, Liu X, McKillop M, Medin J, Qiu H, Zhong N, Liu M, Laffey J, Li Y, Zhang H (2019) Identification and modulation of microenvironment is crucial for effective mesenchymal stromal cell therapy in acute lung injury. Am J Respir Crit Care Med 199:1214\u20131224","journal-title":"Am J Respir Crit Care Med"},{"key":"424_CR76","first-page":"421","volume":"15","author":"M Ullah","year":"2019","unstructured":"Ullah M, Liu DD, Thakor AS (2019) Mesenchymal Stromal Cell Homing: Mechanisms and Strategies for Improvement. Science 15:421\u2013438","journal-title":"Science"},{"key":"424_CR77","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/stem.2922","volume":"37","author":"LMA Murray","year":"2019","unstructured":"Murray LMA, Krasnodembskaya AD (2019) Concise Review: Intercellular Communication Via Organelle Transfer in the Biology and Therapeutic Applications of Stem Cells. Stem Cells 37:14\u201325","journal-title":"Stem Cells"},{"key":"424_CR78","doi-asserted-by":"publisher","first-page":"583017","DOI":"10.3389\/fimmu.2020.583017","volume":"11","author":"T Maron-Gutierrez","year":"2020","unstructured":"Maron-Gutierrez T, Rocco PRM (2020) Cell-Free Therapies: Novel Approaches for COVID-19. Front Immunol 11:583017","journal-title":"Front Immunol"},{"key":"424_CR79","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nm.2736","volume":"18","author":"MN Islam","year":"2012","unstructured":"Islam MN, Das SR, Emin MT, Wei M, Sun L, Westphalen K, Rowlands DJ, Quadri SK, Bhattacharya S, Bhattacharya J (2012) Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med 18:759\u2013765","journal-title":"Nat Med"},{"key":"424_CR80","doi-asserted-by":"publisher","first-page":"e880","DOI":"10.1097\/CCM.0000000000005056","volume":"49","author":"LRP de Carvalho","year":"2021","unstructured":"de Carvalho LRP, Abreu SC, de Castro LL, Andrade da Silva LH, Silva PM, Vieira JB, Santos RT, Cabral MR, Khoury M, Weiss DJ, Lopes-Pacheco M, Silva PL, Cruz FF, Rocco PRM (2021) Mitochondria-Rich Fraction Isolated From Mesenchymal Stromal Cells Reduces Lung and Distal Organ Injury in Experimental Sepsis. Crit Care Med 49:e880","journal-title":"Crit Care Med"},{"key":"424_CR81","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3389\/fimmu.2020.01091","volume":"11","author":"G Moll","year":"2020","unstructured":"Moll G, Drzeniek N, Kamhieh-Milz J, Geissler S, Volk HD, Reinke P (2020) MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy. Front Immunol 11:1091","journal-title":"Front Immunol"},{"key":"424_CR82","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.3389\/fimmu.2019.01228","volume":"10","author":"DJ Weiss","year":"2019","unstructured":"Weiss DJ, English K, Krasnodembskaya A, Isaza-Correa JM, Hawthorne IJ, Mahon BP (2019) The Necrobiology of Mesenchymal Stromal Cells Affects Therapeutic Efficacy. Front Immunol 10:1228","journal-title":"Front Immunol"},{"key":"424_CR83","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1164\/rccm.202101-0218ED","volume":"203","author":"K Reddy","year":"2021","unstructured":"Reddy K, Calfee CS, McAuley DF (2021) Acute Respiratory Distress Syndrome Subphenotypes beyond the Syndrome: A Step toward Treatable Traits? Am J Respir Crit Care Med 203:1449\u20131451","journal-title":"Am J Respir Crit Care Med"},{"key":"424_CR84","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40635-020-0295-5","volume":"8","author":"S Horie","year":"2020","unstructured":"Horie S, Gaynard S, Murphy M, Barry F, Scully M, O\u2019Toole D, Laffey JG (2020) Cytokine pre-activation of cryopreserved xenogeneic-free human mesenchymal stromal cells enhances resolution and repair following ventilator-induced lung injury potentially via a KGF-dependent mechanism. Intensive Care Med Exp 8:8","journal-title":"Intensive Care Med Exp"},{"key":"424_CR85","first-page":"89","volume":"7","author":"S Rolandsson Enes","year":"2021","unstructured":"Rolandsson Enes S, Hampton TH, Barua J, McKenna DH, Dos Santos CC, Amiel E, Ashare A, Liu KD, Krasnodembskaya AD, English K, Stanton BA, Rocco PRM, Matthay MA, Weiss DJ (2021) Healthy versus inflamed lung environments differentially effect MSCs. Eur Respir J 7:89","journal-title":"Eur Respir J"},{"key":"424_CR86","doi-asserted-by":"publisher","first-page":"884","DOI":"10.5966\/sctm.2013-0033","volume":"2","author":"ML Bustos","year":"2013","unstructured":"Bustos ML, Huleihel L, Meyer EM, Donnenberg AD, Donnenberg VS, Sciurba JD, Mroz L, McVerry BJ, Ellis BM, Kaminski N, Rojas M (2013) Activation of human mesenchymal stem cells impacts their therapeutic abilities in lung injury by increasing interleukin (IL)-10 and IL-1RN levels. Stem Cells Transl Med 2:884\u2013895","journal-title":"Stem Cells Transl Med"},{"key":"424_CR87","doi-asserted-by":"publisher","first-page":"L823","DOI":"10.1152\/ajplung.00263.2019","volume":"317","author":"SC Abreu","year":"2019","unstructured":"Abreu SC, Rolandsson Enes S, Dearborn J, Goodwin M, Coffey A, Borg ZD, Dos Santos CC, Wargo MJ, Cruz FF, Loi R, DeSarno M, Ashikaga T, Antunes MA, Rocco PRM, Liu KD, Lee JW, Matthay MA, McKenna DH, Weiss DJ (2019) Lung inflammatory environments differentially alter mesenchymal stromal cell behavior. Am J Physiol Lung Cell Mol Physiol 317:L823\u2013L831","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"424_CR88","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/sctm.18-0056","volume":"8","author":"SC Abreu","year":"2019","unstructured":"Abreu SC, Xisto DG, de Oliveira TB, Blanco NG, de Castro LL, Kitoko JZ, Olsen PC, Lopes-Pacheco M, Morales MM, Weiss DJ, Rocco PRM (2019) Serum from Asthmatic Mice Potentiates the Therapeutic Effects of Mesenchymal Stromal Cells in Experimental Allergic Asthma. Stem Cells Transl Med 8:301\u2013312","journal-title":"Stem Cells Transl Med"},{"key":"424_CR89","doi-asserted-by":"publisher","first-page":"L908","DOI":"10.1152\/ajplung.00218.2020","volume":"319","author":"SC Abreu","year":"2020","unstructured":"Abreu SC, Hampton TH, Hoffman E, Dearborn J, Ashare A, Singh Sidhu K, Matthews DE, McKenna DH, Amiel E, Barua J, Krasnodembskaya A, English K, Mahon B, Dos Santos C, Cruz FF, Chambers DC, Liu KD, Matthay MA, Cramer RA, Stanton BA, Rocco PRM, Wargo MJ, Weiss DJ, Rolandsson Enes S (2020) Differential effects of the cystic fibrosis lung inflammatory environment on mesenchymal stromal cells. Am J Physiol Lung Cell Mol Physiol 319:L908\u2013L925","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"424_CR90","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13287-019-1224-y","volume":"10","author":"NC Noronha","year":"2019","unstructured":"Noronha NC, Mizukami A, Caliari-Oliveira C, Cominal JG, Rocha JLM, Covas DT, Swiech K, Malmegrim KCR (2019) Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies. Stem Cell Res Ther 10:131","journal-title":"Stem Cell Res Ther"},{"key":"424_CR91","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40635-015-0065-y","volume":"3","author":"M Hayes","year":"2015","unstructured":"Hayes M, Curley GF, Masterson C, Devaney J, O\u2019Toole D, Laffey JG (2015) Mesenchymal stromal cells are more effective than the MSC secretome in diminishing injury and enhancing recovery following ventilator-induced lung injury. Intensive Care Med Exp 3:29","journal-title":"Intensive Care Med Exp"},{"key":"424_CR92","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/ijms20184597","volume":"20","author":"S Eleuteri","year":"2019","unstructured":"Eleuteri S, Fierabracci A (2019) Insights into the Secretome of Mesenchymal Stem Cells and Its Potential Applications. Int J Mol Sci 20:7","journal-title":"Int J Mol Sci"},{"key":"424_CR93","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1089\/jamp.2019.1542","volume":"33","author":"SD McCarthy","year":"2020","unstructured":"McCarthy SD, Horgan E, Ali A, Masterson C, Laffey JG, MacLoughlin R, O\u2019Toole D (2020) Nebulized Mesenchymal Stem Cell Derived Conditioned Medium Retains Antibacterial Properties Against Clinical Pathogen Isolates. J Aerosol Med Pulm Drug Deliv 33:140\u2013152","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"424_CR94","doi-asserted-by":"publisher","first-page":"e12134","DOI":"10.1002\/jev2.12134","volume":"10","author":"M-M Shi","year":"2021","unstructured":"Shi M-M, Yang Q-Y, Monsel A, Yan J-Y, Dai C-X, Zhao J-Y, Shi G-C, Zhou M, Zhu X-M, Li S-K, Li P, Wang J, Li M, Lei J-G, Xu D, Zhu Y-G, Qu J-M (2021) Preclinical efficacy and clinical safety of clinical-grade nebulized allogenic adipose mesenchymal stromal cells-derived extracellular vesicles. J Extracellular Vesicles 10:e12134","journal-title":"J Extracellular Vesicles"},{"key":"424_CR95","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1164\/rccm.201206-0990OC","volume":"187","author":"JW Lee","year":"2013","unstructured":"Lee JW, Krasnodembskaya A, McKenna DH, Song Y, Abbott J, Matthay MA (2013) Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. Am J Respir Crit Care Med 187:751\u2013760","journal-title":"Am J Respir Crit Care Med"},{"key":"424_CR96","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1164\/rccm.201410-1765OC","volume":"192","author":"A Monsel","year":"2015","unstructured":"Monsel A, Zhu YG, Gennai S, Hao Q, Hu S, Rouby JJ, Rosenzwajg M, Matthay MA, Lee JW (2015) Therapeutic Effects of Human Mesenchymal Stem Cell-derived Microvesicles in Severe Pneumonia in Mice. Am J Respir Crit Care Med 192:324\u2013336","journal-title":"Am J Respir Crit Care Med"},{"key":"424_CR97","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1080\/14712598.2016.1218845","volume":"16","author":"FF Cruz","year":"2016","unstructured":"Cruz FF, Weiss DJ, Rocco PR (2016) Prospects and progress in cell therapy for acute respiratory distress syndrome. Expert Opin Biol Ther 16:1353\u20131360","journal-title":"Expert Opin Biol Ther"},{"key":"424_CR98","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1164\/rccm.201701-0107CP","volume":"196","author":"JG Laffey","year":"2017","unstructured":"Laffey JG, Matthay MA (2017) Fifty Years of Research in ARDS. Cell-based Therapy for Acute Respiratory Distress Syndrome. Biology and Potential Therapeutic Value. Am J Respir Crit Care Med 196:266\u2013273","journal-title":"Am J Respir Crit Care Med"},{"key":"424_CR99","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1002\/eji.200738129","volume":"38","author":"D Polchert","year":"2008","unstructured":"Polchert D, Sobinsky J, Douglas G, Kidd M, Moadsiri A, Reina E, Genrich K, Mehrotra S, Setty S, Smith B, Bartholomew A (2008) IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 38:1745\u20131755","journal-title":"Eur J Immunol"},{"key":"424_CR100","first-page":"317801","volume":"2015","author":"X Liu","year":"2015","unstructured":"Liu X, Feng T, Gong T, Shen C, Zhu T, Wu Q, Li Q, Li H (2015) Human Umbilical Cord Mesenchymal Stem Cells Inhibit the Function of Allogeneic Activated Vgamma9Vdelta2 T Lymphocytes In Vitro. Biomed Res Int 2015:317801","journal-title":"Biomed Res Int"},{"key":"424_CR101","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/thoraxjnl-2020-215717","volume":"76","author":"M Monguio-Tortajada","year":"2021","unstructured":"Monguio-Tortajada M, Bayes-Genis A, Rosell A, Roura S (2021) Are mesenchymal stem cells and derived extracellular vesicles valuable to halt the COVID-19 inflammatory cascade? Current evidence and future perspectives. Thorax 76:196\u2013200","journal-title":"Thorax"},{"key":"424_CR102","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.1073\/pnas.1601911113","volume":"113","author":"MC Chan","year":"2016","unstructured":"Chan MC, Kuok DI, Leung CY, Hui KP, Valkenburg SA, Lau EH, Nicholls JM, Fang X, Guan Y, Lee JW, Chan RW, Webster RG, Matthay MA, Peiris JS (2016) Human mesenchymal stromal cells reduce influenza A H5N1-associated acute lung injury in vitro and in vivo. Proc Natl Acad Sci U S A 113:3621\u20133626","journal-title":"Proc Natl Acad Sci U S A"},{"key":"424_CR103","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13287-016-0395-z","volume":"7","author":"Y Li","year":"2016","unstructured":"Li Y, Xu J, Shi W, Chen C, Shao Y, Zhu L, Lu W, Han X (2016) Mesenchymal stromal cell treatment prevents H9N2 avian influenza virus-induced acute lung injury in mice. Stem Cell Res Ther 7:159","journal-title":"Stem Cell Res Ther"},{"key":"424_CR104","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/infdis\/jiy478","volume":"219","author":"H Loy","year":"2019","unstructured":"Loy H, Kuok DIT, Hui KPY, Choi MHL, Yuen W, Nicholls JM, Peiris JSM, Chan MCW (2019) Therapeutic Implications of Human Umbilical Cord Mesenchymal Stromal Cells in Attenuating Influenza A(H5N1) Virus-Associated Acute Lung Injury. J Infect Dis 219:186\u2013196","journal-title":"J Infect Dis"},{"key":"424_CR105","doi-asserted-by":"publisher","first-page":"e71761","DOI":"10.1371\/journal.pone.0071761","volume":"8","author":"I Darwish","year":"2013","unstructured":"Darwish I, Banner D, Mubareka S, Kim H, Besla R, Kelvin DJ, Kain KC, Liles WC (2013) Mesenchymal stromal (stem) cell therapy fails to improve outcomes in experimental severe influenza. PLoS ONE 8:e71761","journal-title":"PLoS ONE"},{"key":"424_CR106","doi-asserted-by":"publisher","first-page":"L395","DOI":"10.1152\/ajplung.00110.2014","volume":"307","author":"JE Gotts","year":"2014","unstructured":"Gotts JE, Abbott J, Matthay MA (2014) Influenza causes prolonged disruption of the alveolar-capillary barrier in mice unresponsive to mesenchymal stem cell therapy. Am J Physiol Lung Cell Mol Physiol 307:L395-406","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"424_CR107","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1126\/science.abc5343","volume":"369","author":"W Deng","year":"2020","unstructured":"Deng W, Bao L, Liu J, Xiao C, Liu J, Xue J, Lv Q, Qi F, Gao H, Yu P, Xu Y, Qu Y, Li F, Xiang Z, Yu H, Gong S, Liu M, Wang G, Wang S, Song Z, Liu Y, Zhao W, Han Y, Zhao L, Liu X, Wei Q, Qin C (2020) Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. Science 369:818\u2013823","journal-title":"Science"},{"key":"424_CR108","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41586-020-2312-y","volume":"583","author":"L Bao","year":"2020","unstructured":"Bao L, Deng W, Huang B, Gao H, Liu J, Ren L, Wei Q, Yu P, Xu Y, Qi F, Qu Y, Li F, Lv Q, Wang W, Xue J, Gong S, Liu M, Wang G, Wang S, Song Z, Zhao L, Liu P, Zhao L, Ye F, Wang H, Zhou W, Zhu N, Zhen W, Yu H, Zhang X, Guo L, Chen L, Wang C, Wang Y, Wang X, Xiao Y, Sun Q, Liu H, Zhu F, Ma C, Yan L, Yang M, Han J, Xu W, Tan W, Peng X, Jin Q, Wu G, Qin C (2020) The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 583:830\u2013833","journal-title":"Nature"},{"key":"424_CR109","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13287-016-0317-0","volume":"7","author":"SC Abreu","year":"2016","unstructured":"Abreu SC, Weiss DJ, Rocco PR (2016) Extracellular vesicles derived from mesenchymal stromal cells: a therapeutic option in respiratory diseases? Stem Cell Res Ther 7:53","journal-title":"Stem Cell Res Ther"},{"key":"424_CR110","doi-asserted-by":"publisher","first-page":"9415367","DOI":"10.1155\/2018\/9415367","volume":"2018","author":"J Phelps","year":"2018","unstructured":"Phelps J, Sanati-Nezhad A, Ungrin M, Duncan NA, Sen A (2018) Bioprocessing of Mesenchymal Stem Cells and Their Derivatives: Toward Cell-Free Therapeutics. Stem Cells Int 2018:9415367","journal-title":"Stem Cells Int"},{"key":"424_CR111","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13287-018-0774-8","volume":"9","author":"M Khatri","year":"2018","unstructured":"Khatri M, Richardson LA, Meulia T (2018) Mesenchymal stem cell-derived extracellular vesicles attenuate influenza virus-induced acute lung injury in a pig model. Stem Cell Res Ther 9:17","journal-title":"Stem Cell Res Ther"},{"key":"424_CR112","first-page":"100249","volume":"19","author":"M Thompson","year":"2020","unstructured":"Thompson M, Mei SHJ, Wolfe D, Champagne J, Fergusson D, Stewart DJ, Sullivan KJ, Doxtator E, Lalu M, English SW, Granton J, Hutton B, Marshall J, Maybee A, Walley KR, Santos CD, Winston B, McIntyre L (2020) Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: An updated systematic review and meta-analysis. E Clin Med 19:100249","journal-title":"E Clin Med"},{"key":"424_CR113","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1080\/17476348.2021.1848555","volume":"15","author":"E Gorman","year":"2021","unstructured":"Gorman E, Millar J, McAuley D, O\u2019Kane C (2021) Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential. Expert Rev Respir Med 15:301\u2013324","journal-title":"Expert Rev Respir Med"},{"key":"424_CR114","doi-asserted-by":"publisher","unstructured":"Bellingan G, Jacono F, Bannard-Smith J, Brealey D, Meyer N, Thickett D, Young D, Bentley A, McVerry BJ, Wunderink RG, Doerschug KC, Summers C, Rojas M, Ting A, Jenkins ED (2021) Safety and efficacy of multipotent adult progenitor cells in acute respiratory distress syndrome (MUST-ARDS): a multicentre, randomised, double-blind, placebo-controlled phase 1\/2 trial. Intensive Care Med 23:1\u20139. https:\/\/doi.org\/10.1007\/s00134-021-06570-4","DOI":"10.1007\/s00134-021-06570-4"},{"key":"424_CR115","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1172\/jci.insight.148983","volume":"6","author":"KD Wick","year":"2021","unstructured":"Wick KD, Leligdowicz A, Zhuo H, Ware LB, Matthay MA (2021) Mesenchymal stromal cells reduce evidence of lung injury in patients with ARDS. JCI Insight 6:45","journal-title":"JCI Insight"},{"key":"424_CR116","first-page":"1153","volume":"6","author":"J Chen","year":"2020","unstructured":"Chen J, Hu C, Chen L, Tang L, Zhu Y, Xu X, Chen L, Gao H, Lu X, Yu L, Dai X, Xiang C, Li L (2020) Clinical Study of Mesenchymal Stem Cell Treatment for Acute Respiratory Distress Syndrome Induced by Epidemic Influenza A (H7N9) Infection: A Hint for COVID-19 Treatment. Engineering (Beijing) 6:1153\u20131161","journal-title":"Engineering (Beijing)"},{"key":"424_CR117","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41392-021-00488-5","volume":"6","author":"L Shi","year":"2021","unstructured":"Shi L, Huang H, Lu X, Yan X, Jiang X, Xu R, Wang S, Zhang C, Yuan X, Xu Z, Huang L, Fu JL, Li Y, Zhang Y, Yao WQ, Liu T, Song J, Sun L, Yang F, Zhang X, Zhang B, Shi M, Meng F, Song Y, Yu Y, Wen J, Li Q, Mao Q, Maeurer M, Zumla A, Yao C, Xie WF, Wang FS (2021) Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct Target Ther 6:58","journal-title":"Signal Transduct Target Ther"},{"key":"424_CR118","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/sctm.20-0472","volume":"10","author":"G Lanzoni","year":"2021","unstructured":"Lanzoni G, Linetsky E, Correa D, Messinger Cayetano S, Alvarez RA, Kouroupis D, Alvarez Gil A, Poggioli R, Ruiz P, Marttos AC, Hirani K, Bell CA, Kusack H, Rafkin L, Baidal D, Pastewski A, Gawri K, Lenero C, Mantero AMA, Metalonis SW, Wang X, Roque L, Masters B, Kenyon NS, Ginzburg E, Xu X, Tan J, Caplan AI, Glassberg MK, Alejandro R, Ricordi C (2021) Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1\/2a, randomized controlled trial. Stem Cells Transl Med 10:660\u2013673","journal-title":"Stem Cells Transl Med"},{"key":"424_CR119","first-page":"563","volume":"8","author":"IH Dilogo","year":"2021","unstructured":"Dilogo IH, Aditianingsih D, Sugiarto A, Burhan E, Damayanti T, Sitompul PA, Mariana N, Antarianto RD, Liem IK, Kispa T, Mujadid F, Novialdi N, Luviah E, Kurniawati T, Lubis AMT, Rahmatika D (2021) Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: A randomized controlled trial. Stem Cells Transl Med 8:563","journal-title":"Stem Cells Transl Med"},{"key":"424_CR120","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1186\/s13063-020-04416-w","volume":"21","author":"E Gorman","year":"2020","unstructured":"Gorman E, Shankar-Hari M, Hopkins P, Tunnicliffe WS, Perkins GD, Silversides J, McGuigan P, Jackson C, Boyle R, McFerran J, McDowell C, Campbell C, McFarland M, Smythe J, Thompson J, Williams B, Curley G, Laffey JG, Clarke M, O\u2019Kane C, McAuley DF (2020) Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial. Trials 21:462","journal-title":"Trials"},{"key":"424_CR121","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/S2213-2600(14)70291-7","volume":"3","author":"JG Wilson","year":"2015","unstructured":"Wilson JG, Liu KD, Zhuo H, Caballero L, McMillan M, Fang X, Cosgrove K, Vojnik R, Calfee CS, Lee JW, Rogers AJ, Levitt J, Wiener-Kronish J, Bajwa EK, Leavitt A, McKenna D, Thompson BT, Matthay MA (2015) Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med 3:24\u201332","journal-title":"Lancet Respir Med"},{"key":"424_CR122","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S2213-2600(18)30418-1","volume":"7","author":"MA Matthay","year":"2019","unstructured":"Matthay MA, Calfee CS, Zhuo H, Thompson BT, Wilson JG, Levitt JE, Rogers AJ, Gotts JE, Wiener-Kronish JP, Bajwa EK, Donahoe MP, McVerry BJ, Ortiz LA, Exline M, Christman JW, Abbott J, Delucchi KL, Caballero L, McMillan M, McKenna DH, Liu KD (2019) Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med 7:154\u2013162","journal-title":"Lancet Respir Med"},{"key":"424_CR123","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1164\/rccm.201306-1043OC","volume":"189","author":"ML Bustos","year":"2014","unstructured":"Bustos ML, Huleihel L, Kapetanaki MG, Lino-Cardenas CL, Mroz L, Ellis BM, McVerry BJ, Richards TJ, Kaminski N, Cerdenes N, Mora AL, Rojas M (2014) Aging mesenchymal stem cells fail to protect because of impaired migration and antiinflammatory response. Am J Respir Crit Care Med 189:787\u2013798","journal-title":"Am J Respir Crit Care Med"},{"key":"424_CR124","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S1465324921002954","volume":"23","author":"KBN Hashimoto","year":"2021","unstructured":"Hashimoto KBN, Enkhbaatar P, Angel M, Lader A, Czuczman M, Matthay MA (2021) Novel Induced-Mesenchymal Stem Cells (i-MSCs) Attenuate Severity of ARDS in Septic Sheep. Cytotherapy 23:5","journal-title":"Cytotherapy"},{"key":"424_CR125","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1097\/ALN.0000000000002653","volume":"130","author":"JW Lee","year":"2019","unstructured":"Lee JW, Matthay MA (2019) Is a part better than the whole for cell-based therapy for acute respiratory distress syndrome? Anesthesiology 130:683\u2013685","journal-title":"Anesthesiology"},{"key":"424_CR126","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1136\/thoraxjnl-2015-206813","volume":"70","author":"J Devaney","year":"2015","unstructured":"Devaney J, Horie S, Masterson C, Elliman S, Barry F, O\u2019Brien T, Curley GF, O\u2019Toole D, Laffey JG (2015) Human mesenchymal stromal cells decrease the severity of acute lung injury induced by E. coli in the rat. Thorax 70:625\u2013635","journal-title":"Thorax"},{"key":"424_CR127","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1002\/stem.2891","volume":"36","author":"D Perlee","year":"2018","unstructured":"Perlee D, van Vught LA, Scicluna BP, Maag A, Lutter R, Kemper EM, van \u2019t Veer C, Punchard MA, Gonzalez J, Richard MP, Dalemans W, Lombardo E, de Vos AF, van der Poll T, (2018) Intravenous Infusion of Human Adipose Mesenchymal Stem Cells Modifies the Host Response to Lipopolysaccharide in Humans: A Randomized, Single-Blind, Parallel Group, Placebo Controlled Trial. Stem Cells 36:1778\u20131788","journal-title":"Stem Cells"},{"key":"424_CR128","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ebiom.2016.09.011","volume":"12","author":"DK Packham","year":"2016","unstructured":"Packham DK, Fraser IR, Kerr PG, Segal KR (2016) Allogeneic Mesenchymal Precursor Cells (MPC) in Diabetic Nephropathy: A Randomized, Placebo-controlled, Dose Escalation Study. EBioMedicine 12:263\u2013269","journal-title":"EBioMedicine"},{"key":"424_CR129","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/sctm.19-0202","volume":"9","author":"M Kabat","year":"2020","unstructured":"Kabat M, Bobkov I, Kumar S, Grumet M (2020) Trends in mesenchymal stem cell clinical trials 2004\u20132018: Is efficacy optimal in a narrow dose range? Stem Cells Transl Med 9:17\u201327","journal-title":"Stem Cells Transl Med"},{"key":"424_CR130","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1136\/thoraxjnl-2013-204980","volume":"69","author":"S Asmussen","year":"2014","unstructured":"Asmussen S, Ito H, Traber DL, Lee JW, Cox RA, Hawkins HK, McAuley DF, McKenna DH, Traber LD, Zhuo H, Wilson J, Herndon DN, Prough DS, Liu KD, Matthay MA, Enkhbaatar P (2014) Human mesenchymal stem cells reduce the severity of acute lung injury in a sheep model of bacterial pneumonia. Thorax 69:819\u2013825","journal-title":"Thorax"},{"key":"424_CR131","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2213-2600(14)70097-9","volume":"2","author":"CS Calfee","year":"2014","unstructured":"Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA, Network NA (2014) Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med 2:611\u2013620","journal-title":"Lancet Respir Med"},{"key":"424_CR132","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-2600(18)30177-2","volume":"6","author":"CS Calfee","year":"2018","unstructured":"Calfee CS, Delucchi KL, Sinha P, Matthay MA, Hackett J, Shankar-Hari M, McDowell C, Laffey JG, O\u2019Kane CM, McAuley DF, Trials ICC, G, (2018) Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir Med 6:691\u2013698","journal-title":"Lancet Respir Med"},{"key":"424_CR133","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1007\/s00134-020-06296-9","volume":"46","author":"MA Matthay","year":"2020","unstructured":"Matthay MA, Arabi YM, Siegel ER, Ware LB, Bos LDJ, Sinha P, Beitler JR, Wick KD, Curley MAQ, Constantin JM, Levitt JE, Calfee CS (2020) Phenotypes and personalized medicine in the acute respiratory distress syndrome. Intensive Care Med 46:2136\u20132152","journal-title":"Intensive Care Med"},{"key":"424_CR134","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S2213-2600(19)30369-8","volume":"8","author":"P Sinha","year":"2020","unstructured":"Sinha P, Delucchi KL, McAuley DF, O\u2019Kane CM, Matthay MA, Calfee CS (2020) Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials. Lancet Respir Med 8:247\u2013257","journal-title":"Lancet Respir Med"},{"key":"424_CR135","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/thoraxjnl-2017-211280","volume":"73","author":"MA Warren","year":"2018","unstructured":"Warren MA, Zhao Z, Koyama T, Bastarache JA, Shaver CM, Semler MW, Rice TW, Matthay MA, Calfee CS, Ware LB (2018) Severity scoring of lung oedema on the chest radiograph is associated with clinical outcomes in ARDS. Thorax 73:840\u2013846","journal-title":"Thorax"},{"key":"424_CR136","doi-asserted-by":"publisher","first-page":"216","DOI":"10.14336\/AD.2020.0228","volume":"11","author":"Z Leng","year":"2020","unstructured":"Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, Shan G, Meng F, Du D, Wang S, Fan J, Wang W, Deng L, Shi H, Li H, Hu Z, Zhang F, Gao J, Liu H, Li X, Zhao Y, Yin K, He X, Gao Z, Wang Y, Yang B, Jin R, Stambler I, Lim LW, Su H, Moskalev A, Cano A, Chakrabarti S, Min KJ, Ellison-Hughes G, Caruso C, Jin K, Zhao RC (2020) Transplantation of ACE2(-) Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. Aging Dis 11:216\u2013228","journal-title":"Aging Dis"},{"key":"424_CR137","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s12015-020-09976-7","volume":"16","author":"H Ulrich","year":"2020","unstructured":"Ulrich H, Pillat MM (2020) CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement. Stem Cell Rev Rep 16:434\u2013440","journal-title":"Stem Cell Rev Rep"},{"key":"424_CR138","doi-asserted-by":"publisher","first-page":"e1009","DOI":"10.1038\/cddis.2013.537","volume":"5","author":"X Chen","year":"2014","unstructured":"Chen X, Gan Y, Li W, Su J, Zhang Y, Huang Y, Roberts AI, Han Y, Li J, Wang Y, Shi Y (2014) The interaction between mesenchymal stem cells and steroids during inflammation. Cell Death Dis 5:e1009","journal-title":"Cell Death Dis"},{"key":"424_CR139","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/S0140-6736(14)62449-1","volume":"385","author":"J Dobson","year":"2015","unstructured":"Dobson J, Whitley RJ, Pocock S, Monto AS (2015) Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet 385:1729\u20131737","journal-title":"Lancet"},{"key":"424_CR140","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/508439a","volume":"508","author":"D Butler","year":"2014","unstructured":"Butler D (2014) Tamiflu report comes under fire. Nature 508:439\u2013440","journal-title":"Nature"},{"key":"424_CR141","doi-asserted-by":"publisher","first-page":"e60348","DOI":"10.1371\/journal.pone.0060348","volume":"8","author":"B Michiels","year":"2013","unstructured":"Michiels B, Van Puyenbroeck K, Verhoeven V, Vermeire E, Coenen S (2013) The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews. PLoS ONE 8:e60348","journal-title":"PLoS ONE"},{"key":"424_CR142","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1093\/fampra\/cms059","volume":"30","author":"MH Ebell","year":"2013","unstructured":"Ebell MH, Call M, Shinholser J (2013) Effectiveness of oseltamivir in adults: a meta-analysis of published and unpublished clinical trials. Fam Pract 30:125\u2013133","journal-title":"Fam Pract"},{"key":"424_CR143","doi-asserted-by":"publisher","first-page":"g2547","DOI":"10.1136\/bmj.g2547","volume":"348","author":"CJ Heneghan","year":"2014","unstructured":"Heneghan CJ, Onakpoya I, Thompson M, Spencer EA, Jones M, Jefferson T (2014) Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 348:g2547","journal-title":"BMJ"},{"key":"424_CR144","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1542\/peds.2016-2727","volume":"140","author":"JS Bradley","year":"2017","unstructured":"Bradley JS, Blumer JL, Romero JR, Michaels MG, Munoz FM, Kimberlin DW, Pahud B, DeBiasi RL, Yamamoto G, Roberts G, Hossain M, Shortino D, Yates PJ, Adams B, Peppercorn A (2017) Intravenous Zanamivir in Hospitalized Patients With Influenza. Pediatrics 140:8","journal-title":"Pediatrics"},{"key":"424_CR145","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S2213-2600(16)30435-0","volume":"5","author":"FM Marty","year":"2017","unstructured":"Marty FM, Vidal-Puigserver J, Clark C, Gupta SK, Merino E, Garot D, Chapman MJ, Jacobs F, Rodriguez-Noriega E, Husa P, Shortino D, Watson HA, Yates PJ, Peppercorn AF (2017) Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial. Lancet Respir Med 5:135\u2013146","journal-title":"Lancet Respir Med"},{"key":"424_CR146","doi-asserted-by":"publisher","first-page":"5267","DOI":"10.1128\/AAC.00360-11","volume":"55","author":"Kohno S, Yen MY, Cheong HJ, Hirotsu N, Ishida T, Kadota J, Mizuguchi M, Kida H, Shimada J, Group SCS","year":"2011","unstructured":"Kohno S, Yen MY, Cheong HJ, Hirotsu N, Ishida T, Kadota J, Mizuguchi M, Kida H, Shimada J, Group SCS (2011) Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother 55:5267\u20135276","journal-title":"Antimicrob Agents Chemother"},{"key":"424_CR147","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/1471-2334-11-134","volume":"11","author":"K Thorlund","year":"2011","unstructured":"Thorlund K, Awad T, Boivin G, Thabane L (2011) Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infect Dis 11:134","journal-title":"BMC Infect Dis"},{"key":"424_CR148","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa1716197","volume":"379","author":"FG Hayden","year":"2018","unstructured":"Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, Ishida T, Sekino H, Yamada K, Portsmouth S, Kawaguchi K, Shishido T, Arai M, Tsuchiya K, Uehara T, Watanabe A, Baloxavir Marboxil Investigators G (2018) Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med 379:913\u2013923","journal-title":"N Engl J Med"},{"key":"424_CR149","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1097\/INF.0000000000002747","volume":"39","author":"J Baker","year":"2020","unstructured":"Baker J, Block SL, Matharu B, Burleigh Macutkiewicz L, Wildum S, Dimonaco S, Collinson N, Clinch B, Piedra PA (2020) Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2). Pediatr Infect Dis J 39:700\u2013705","journal-title":"Pediatr Infect Dis J"},{"key":"424_CR150","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1097\/INF.0000000000002748","volume":"39","author":"T Yokoyama","year":"2020","unstructured":"Yokoyama T, Sakaguchi H, Ishibashi T, Shishido T, Piedra PA, Sato C, Tsuchiya K, Uehara T (2020) Baloxavir Marboxil 2% Granules in Japanese Children With Influenza: An Open-label Phase 3 Study. Pediatr Infect Dis J 39:706\u2013712","journal-title":"Pediatr Infect Dis J"},{"key":"424_CR151","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1056\/NEJMoa1915341","volume":"383","author":"H Ikematsu","year":"2020","unstructured":"Ikematsu H, Hayden FG, Kawaguchi K, Kinoshita M, de Jong MD, Lee N, Takashima S, Noshi T, Tsuchiya K, Uehara T (2020) Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts. N Engl J Med 383:309\u2013320","journal-title":"N Engl J Med"},{"key":"424_CR152","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s40261-018-0710-9","volume":"38","author":"H Koshimichi","year":"2018","unstructured":"Koshimichi H, Ishibashi T, Kawaguchi N, Sato C, Kawasaki A, Wajima T (2018) Safety, Tolerability, and Pharmacokinetics of the Novel Anti-influenza Agent Baloxavir Marboxil in Healthy Adults: Phase I Study Findings. Clin Drug Investig 38:1189\u20131196","journal-title":"Clin Drug Investig"},{"key":"424_CR153","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.jiac.2021.06.004","volume":"27","author":"T Nakano","year":"2021","unstructured":"Nakano T, Yamaguchi H, Chiba T, Shiosakai K, Chikada S, Matsuoka Y (2021) The safety and efficacy of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate for Inhalation Suspension Set in children under the age of 5 in a post-marketing surveillance. J Infect Chemother 27:1436\u20131446","journal-title":"J Infect Chemother"},{"key":"424_CR154","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1086\/656802","volume":"51","author":"Watanabe A, Chang SC, Kim MJ, Chu DW, Ohashi Y, Group MS","year":"2010","unstructured":"Watanabe A, Chang SC, Kim MJ, Chu DW, Ohashi Y, Group MS (2010) Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial. Clin Infect Dis 51:1167\u20131175","journal-title":"Clin Infect Dis"},{"key":"424_CR155","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1128\/AAC.00333-08","volume":"53","author":"M Yamashita","year":"2009","unstructured":"Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, Kubo S (2009) CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother 53:186\u2013192","journal-title":"Antimicrob Agents Chemother"},{"key":"424_CR156","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/14787210.2018.1421945","volume":"16","author":"N Hirotsu","year":"2018","unstructured":"Hirotsu N, Saisho Y, Hasegawa T, Shishido T (2018) Clinical and virologic effects of four neuraminidase inhibitors in influenza A virus-infected children (aged 4\u201312 years): an open-label, randomized study in Japan. Expert Rev Anti Infect Ther 16:173\u2013182","journal-title":"Expert Rev Anti Infect Ther"}],"container-title":["Intensive Care Medicine Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40635-021-00424-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40635-021-00424-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40635-021-00424-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T21:14:17Z","timestamp":1676063657000},"score":1,"resource":{"primary":{"URL":"https:\/\/icm-experimental.springeropen.com\/articles\/10.1186\/s40635-021-00424-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,31]]},"references-count":156,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["424"],"URL":"https:\/\/doi.org\/10.1186\/s40635-021-00424-5","relation":{},"ISSN":["2197-425X"],"issn-type":[{"value":"2197-425X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,31]]},"assertion":[{"value":"11 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"See COI forms for each author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}